GT Biopharma, Inc.

GTBP · NASDAQ
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Activities
Net Income-$13,162-$7,597-$20,884-$58,013
Dep. & Amort.$0$0$0$0
Deferred Tax$0$0$0$0
Stock-Based Comp.$230$2,200$7,646$33,929
Change in WC$828$1,825-$1,989$7,940
Other Non-Cash-$800-$5,280$10$538
Operating Cash Flow-$12,904-$8,852-$15,217-$15,606
Investing Activities
PP&E Inv.$0$0$0$0
Net Acquisitions$0$0$0$0
Inv. Purchases$12,893$0$12,145-$23,040
Inv. Sales/Matur.$0$0$12,145$0
Other Inv. Act.$0-$2,009-$12,145$0
Investing Cash Flow$12,893-$2,009$12,145-$23,040
Financing Activities
Debt Repay.$0$0$0$1,205
Stock Issued$2,976$6,268$0$24,679
Stock Repurch.$0$0-$224$0
Dividends Paid$0$0$0$0
Other Fin. Act.$0$0$0$16,433
Financing Cash Flow$2,976$6,268-$224$42,317
Forex Effect$0$0$0$0
Net Chg. in Cash$2,965-$4,593-$3,296$3,671
Supplemental Information
Beg. Cash$1,079$5,672$8,968$5,297
End Cash$4,044$1,079$5,672$8,968
Free Cash Flow-$12,904-$8,852-$15,217-$15,606